LakeShore Biopharma Goes Private in Amended Merger Deal

LakeShore Biopharma Co., Ltd, a global biopharmaceutical company specializing in vaccines and therapeutic biologics for infectious diseases and cancer, has entered into an amended merger agreement to go private. The amendment follows a revised proposal from the Buyer Group, led by Oceanpine Skyline Inc., reducing the merger consideration from US$0.90 to US$0.066 per share, implying an equity value of approximately US$2.7 million. The deal will be funded through a cash contribution from Oceanpine Capital Inc. and equity rollover by the Rollover Shareholders, who collectively hold about 53.35% of voting rights. The transaction, expected to close in Q3 2026, will result in LakeShore Biopharma becoming a wholly owned subsidiary of Parent and delisting from the OTC Pink Open Market.

The revised per-share consideration of US$0.066 represents a 46.7% premium over the closing price on March 24, 2026, the day before the revised proposal was announced. The Amended Merger Agreement extends the termination date to nine months from signing, reduces the Company Termination Fee to US$50,000, and the Parent Termination Fee to US$100,000. The Board's Special Committee, advised by Kroll, LLC and legal counsel, unanimously approved the amended terms. Shareholders must authorize the merger by a two-thirds vote at a general meeting, with the Rollover Shareholders committed to voting in favor.

LakeShore Biopharma, previously known as YS Biopharma, operates in China, Singapore, and the Philippines, leveraging its proprietary PIKA® immunomodulating technology platform. The company focuses on developing vaccines and biologics targeting Rabies, Hepatitis B, Influenza, and other viral infections. The merger will allow the company to continue its mission as a private entity, with the original release available on NEWMEDIAWIRE. Investors and shareholders are urged to review the Schedule 13E-3 and other SEC filings for detailed information about the transaction.